Fusions involving RUNX1-RUNX1T1 and CBFB-MYH11, collectively referred to as core binding factor (CBF) AML, are one of the most frequent and most-studied genomic events in AML[5, 6]. This evidence concerns the gene MYH11 and acute myeloid leukemia.